Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
881.3 DKK | -0.79% | -1.41% | +26.24% |
07:00am | Weight-loss drug deals to drive around 4% of Gerresheimer yearly growth, CEO says | RE |
Mar. 28 | Novo Nordisk Asked by Bernie Sanders to Lower List Price of Diabetes, Weight-Loss Drug | MT |
Sales 2024 * | 287B 41.4B | Sales 2025 * | 345B 49.76B | Capitalization | 3,932B 568B |
---|---|---|---|---|---|
Net income 2024 * | 103B 14.92B | Net income 2025 * | 124B 17.92B | EV / Sales 2024 * | 13.8 x |
Net Debt 2024 * | 26.04B 3.76B | Net Debt 2025 * | 3.19B 461M | EV / Sales 2025 * | 11.4 x |
P/E ratio 2024 * |
38.1
x | P/E ratio 2025 * |
31.3
x | Employees | 63,845 |
Yield 2024 * |
1.37% | Yield 2025 * |
1.65% | Free-Float | 70.47% |
Latest transcript on Novo Nordisk A/S
1 day | -0.79% | ||
1 week | -1.41% | ||
Current month | +7.51% | ||
1 month | +5.66% | ||
3 months | +26.22% | ||
6 months | +35.27% | ||
Current year | +26.24% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 90-12-31 | |
Director of Finance/CFO | 53 | 98-12-31 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 15-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 63 | 15-03-18 |
Helge Lund
CHM | Chairman | 61 | 17-03-22 |
Martin MacKay
BRD | Director/Board Member | 68 | 18-02-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
21.31% | 196 M€ | +12.16% | ||
10.45% | 5 M€ | +12.89% | ||
5.40% | 18 M€ | +6.77% | - | |
4.67% | 88 M€ | +10.37% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 881.3 | -0.79% | 2,544,307 |
24-03-26 | 888.3 | -0.69% | 2,930,730 |
24-03-25 | 894.5 | +0.82% | 1,462,573 |
24-03-22 | 887.2 | -0.75% | 2,198,005 |
24-03-21 | 893.9 | -0.90% | 3,529,581 |
Delayed Quote Nasdaq Copenhagen, March 27, 2024 at 11:59 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.24% | 570B | |
+33.46% | 701B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 322B | |
+0.74% | 209B | |
+2.95% | 212B | |
-6.05% | 205B | |
-3.61% | 157B | |
-1.28% | 152B |